Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLO1 | Q04760 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3930383 | 1.00 | GLO1 (0.37) | GLO1ALDH1A1LMNAHSD17B10TSHR | |
| SCHEMBL3919618 | 0.78 | TSHR (0.39) | GLO1ALDH1A1TSHRMAPTNPSR1 | |
| SCHEMBL3919616 | 0.78 | TSHR (0.39) | GLO1ALDH1A1TSHRMAPTNPSR1 | |
| SCHEMBL16843451 | 0.76 | TSHR (0.40) | GLO1ALDH1A1LMNAHSD17B10TSHR | |
| Ethyl Acetate SCHEMBL27578297 | 0.73 | ALDH1A1 (0.64) | GLO1ALDH1A1LMNAHSD17B10TSHR | |
| SCHEMBL10720114 | 0.71 | TSHR (0.40) | ALDH1A1LMNAHSD17B10TSHRMAPT | |
| SCHEMBL6370305 | 0.71 | ALDH1A1 (0.48) | GLO1ALDH1A1LMNAHSD17B10TSHR | |
| SCHEMBL10444832 | 0.70 | SOAT1 (0.44) | GLO1ALDH1A1LMNAHSD17B10TSHR | |
| SCHEMBL1245485 | 0.70 | ALDH1A1 (0.44) | GLO1ALDH1A1LMNAHSD17B10TSHR | |
| SCHEMBL17960733 | 0.70 | ALDH1A1 (0.44) | GLO1ALDH1A1LMNAHSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550607-B2 | Method of preparation of heterocyclic molecules with pharmaceutical, pharmaceutical excipient, cosmeceutical, agrochemical and industrial uses | AUSPEX PHARMACEUTICAL, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20060173199-A1 | Method of preparation of heterocyclic molecules with pharmaceutical, pharmaceutical excipient, cosmeceutical, agrochemical and industrial uses | HONG BORCHERNG | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173199-A1 | Method of preparation of heterocyclic molecules with pharmaceutical, pharmaceutical excipient, cosmeceutical, agrochemical and industrial uses | LSS, DHPS, CYP51A1 | GLO1 2172/4885ALDH1A1 1435/4885LMNA 1693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.